NOVAVAX INC Operating Expenses
NOVAVAX INC (NVAX) reported Operating Expenses of $8.98 million for the 3-month period ending 2011-09-30, per its 10-Q filed 2011-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2011-11-08
- NOVAVAX INC operating expenses for the quarter ending 2011-09-30 was $8.98M, a 16.22% decline year-over-year.
- NOVAVAX INC operating expenses for the quarter ending 2011-06-30 was $8.92M, a 5.84% decline year-over-year.
- NOVAVAX INC operating expenses for the quarter ending 2010-09-30 was $10.71M.
- NOVAVAX INC operating expenses for the quarter ending 2010-06-30 was $9.47M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month |
|---|---|---|---|
| 2011-09-30 | $8.98M 10-Q · filed 2011-11-08 | $17.90M derived: sum of 2 quarters · filed 2011-11-08 | $26.16M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $8.92M 10-Q · filed 2011-08-09 | $17.19M 10-Q · filed 2011-08-09 | |
| 2010-09-30 | $10.71M 10-Q · filed 2011-11-08 | $20.19M derived: sum of 2 quarters · filed 2011-11-08 | $31.75M 10-Q · filed 2011-11-08 |
| 2010-06-30 | $9.47M 10-Q · filed 2011-08-09 | $21.04M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |